Seikagaku reported 3Q20 orthopedic revenue of USD $32.8 million, -8.9% vs. 3Q19. The market forces impacting the company remain largely unchanged from last quarter. The company’s ARTZ viscosupplement continued to take market share in Japan, but decreases in outpatient procedures due to COVID and drug price reductions offset those gains. The U.S. market softened due to pandemic-related procedure restrictions, and Seikagaku’s sales of SUPARTZ FX five-injection treatment continued to erode as the market shifts toward single-injection products.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q20
3Q19
$ Chg
% Chg
Orthobiologics
$32.8
$36.0
($3.2)
(8.9%)
9mo20
9mo19
$ Chg
% Chg
Orthobiologics
$92.9
$114.1
($21.1)
(18.5%)
Geographic Sales
3Q20
3Q19
$ Chg
% Chg
Domestic (Japan)
$15.4
$19.4
($4.0)
(20.7%)
International
$17.4
$16.6
$0.8
5%
Total
$32.8
$36.0
($3.2)
(8.9%)
9mo20
9mo19
$ Chg
% Chg
Domestic (Japan)
$44.3
$52.9
($8.5)
(16.2%)
International
$48.6
$61.2
($12.6)
(20.6%)
Total
$92.9
$114.1
($21.1)
(18.5%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported 3Q20 orthopedic revenue of USD $32.8 million, -8.9% vs. 3Q19. The market forces impacting the company remain largely unchanged from last quarter. The company’s ARTZ viscosupplement continued to take market share in Japan, but decreases in outpatient procedures due to COVID and drug price reductions offset those gains. The...
Seikagaku reported 3Q20 orthopedic revenue of USD $32.8 million, -8.9% vs. 3Q19. The market forces impacting the company remain largely unchanged from last quarter. The company’s ARTZ viscosupplement continued to take market share in Japan, but decreases in outpatient procedures due to COVID and drug price reductions offset those gains. The U.S. market softened due to pandemic-related procedure restrictions, and Seikagaku’s sales of SUPARTZ FX five-injection treatment continued to erode as the market shifts toward single-injection products.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q20
3Q19
$ Chg
% Chg
Orthobiologics
$32.8
$36.0
($3.2)
(8.9%)
9mo20
9mo19
$ Chg
% Chg
Orthobiologics
$92.9
$114.1
($21.1)
(18.5%)
Geographic Sales
3Q20
3Q19
$ Chg
% Chg
Domestic (Japan)
$15.4
$19.4
($4.0)
(20.7%)
International
$17.4
$16.6
$0.8
5%
Total
$32.8
$36.0
($3.2)
(8.9%)
9mo20
9mo19
$ Chg
% Chg
Domestic (Japan)
$44.3
$52.9
($8.5)
(16.2%)
International
$48.6
$61.2
($12.6)
(20.6%)
Total
$92.9
$114.1
($21.1)
(18.5%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
